Challenges, opportunities arise


Continuing trend and new issues defining the current state of glaucoma care

The world of glaucoma management in 2012 is feeling the impact of not only a variety of challenges, but also new opportunities, said Dr Andrew G. Iwach, at Glaucoma Symposium 2012.

Dr Iwach, associate clinical professor of ophthalmology, University of California, San Francisco, California, USA, presented a snapshot of current medical, surgical and practice management issues pertaining to glaucoma patient care. The symposium was held at Glaucoma 360°, which was presented in association with Ophthalmology Times.

"These issues are creating new challenges. Therefore, I always ask my patients to bring in their bottles when they come in for a follow-up visit because I want to see what they are using and where it is from," said Dr Iwach.

He added that he is particularly concerned if there seems to be a sudden loss of IOP control or the patient has developed side effects that can't readily be explained. If tolerability is an issue, clinicians should consider the possibility of a preservative allergy.

"In my experience, the preservative used in the formulation can make a difference for certain patients. Fortunately, there are a number of alternatives to choose from, including products containing preservatives other than benzalkonium chloride or that are preservative-free," Dr Iwach said.

Data on glaucoma surgical procedures show a continued rise in the number of laser trabeculoplasty and tube procedures as trabeculectomy cases decrease.

"I think these numbers reflect acknowledgement that the outcomes of trabeculectomy are really not what we would like them to be and indicate perhaps we should be reexamining how we define success when evaluating new glaucoma surgical procedures. Maybe we should be looking at outcomes from the patient's perspective because we treat individuals, not averages," Dr Iwach said.

Although newer techniques may not lower IOP as much as trabeculectomy, that needs to be balanced against the risks of each procedure in context of a specific patient's situation.

"If we focus on judiciously choosing an intervention based on who is having the surgery, having different methods available becomes very important," said Dr Iwach.

Another recent development has been the introduction of new ICD-9-CM glaucoma diagnosis codes. Dr Iwach acknowledged that while he first reacted to the information about new staging severity codes by thinking it was just an added nuisance, he recognizes their value.

"With these new codes, we can identify patients with severe disease [that is] more difficult to manage and will require more surgery and more testing. Thus, there will be a way to parse out resource use data that will ensure patients get appropriate care and that we have the right infrastructure to provide it," Dr Iwach said.

Treating glaucoma in today's world also requires that practitioners pay attention to themselves. Growing demand for eyecare services in the population requires strategies for increasing office efficiency, but practitioners also need to consider how it will affect their risk of occupational injuries from performing repetitive activities, said Dr Iwach.

"When you are busy and focused on the patient, ergonomics can be overlooked. However, a simple manoeuver, like adjusting the angle of the operating microscope, can make a huge difference over time for physical well-being and enable us to meet the future challenge of handling an increasing volume of patients," he explained.

Recent Videos
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
© 2024 MJH Life Sciences

All rights reserved.